Arkansas judge Tim Fox, who ruled earlier this year that Janssen Pharmaceuticals and its parent company Johnson & Johnson had concealed risks associated with their antipsychotic Risperdal and levied a fine of $1.2 billion, has denied a J&J request for a new trial. In other news, sources say that J&J is within two weeks of a final settlement with federal prosecutors to resolve allegations of using deceptive tactics to market Risperdal. J&J hopes to avoid a felony charge that would prevent it from marketing Risperdal to government health programs such as medicare.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.